Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

FDA released a final rule on protections for children in clinical trials and a final guidance on financial disclosures by investigators. More regulatory news.

You may also be interested in...



Regulatory Roundup: St. Jude Resolves Warning Letter; DePuy Synthes Recall; Syphilis Screening Guidance

St. Jude Medical resolves neuromodulation device facility warning letter; Depuy Synthes craniomaxillofacial distraction system recall tapped as class I; FDA recommends syphilis screening test policies.

Regulatory News In Brief

FDA issues guidance documents on PMA and 510(k) user fees and refunds. Agency issues proposed order for three pre-amendment devices. More regulatory news.

FDA May Disclose Clinical Investigator Financial Data In Product Approvals

Final guidance on drug sponsors’ responsibilities for financial disclosures related to clinical investigators who participate revises definitions of due diligence and covered clinical studies from the draft published in 2011, but retains FDA’s statement that it may include such disclosures in the documents released upon product approval for marketing.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel